Efficacy and safety of reduced dose of Dabigatran, Rivaroxaban and Apixaban in patients with atrial fibrillation for stroke prevention.
Phase of Trial: Phase IV
Latest Information Update: 01 Jan 2018
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Apixaban; Dabigatran etexilate
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- 01 Jan 2018 Results published in the Journal of Internal Medicine
- 29 Sep 2017 New trial record
- 30 Aug 2017 Results (n=23633) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.